Jiangsu Recbio Technology Co., Ltd., a vaccine company, engages in the research, development, and commercialization of subunit vaccines in the People's Republic of China. The company develops vaccines for the treatment of cervical cancers, and anal and genital warts, including REC603, a recombinant human papillomavirus (HPV) 9-valent vaccine that is in phase III clinical trial; REC601 and REC602 recombinant HPV bivalent vaccines targeting HPV type 6/11, which are in phase I clinical trials; REC604a, a recombinant HPV quadrivalent vaccine that is in pre-clinical stage; REC604c, a recombinant HPV 9-valent vaccine; and REC604a, a novel adjuvanted recombinant HPV quadrivalent vaccine. It also develops ReCOV, a recombinant bicomponent COVID-19 vaccine candidate that is in Phase II/III trial; REC610, a recombinant shingles vaccine that is in Phase l clinical trial; and REC617, a recombinant influenza quadrivalent vaccine that is in pre-clinical stage. In addition, the company's vaccine pipeline consists of various pre-clinical stage products for respiratory diseases caused by respiratory syncytial virus (RSV)/ metapneumovirus infection, human cytomegalovirus disease, disease caused by hepatitis B virus infection, and herpes caused by herpes simplex infection. Jiangsu Recbio Technology Co., Ltd. was founded in 2011 and is headquartered in Taizhou, the People's Republic of China.